News

News and Press Releases
CFTR Modulators FDA Approves Trikafta for Children Ages 6 Through 11 With Certain Mutations

The U.S. Food and Drug Administration has approved the use of Trikafta® (elexacaftor/tezacaftor/ivacaftor) for children ages 6 through 11 who have at least one copy of the F508del mutation or certain mutations in the CFTR gene that are responsive based on lab data.

| 4 min read